Numerous therapies are currently available to modify the disease course of multiple
sclerosis (MS). Magnetic resonance imaging (MRI) plays a pivotal role in assessing …

Background: Oral cladribine has been approved for the treatment of relapsing multiple
sclerosis (MS) yet real-world evidence regarding its effectiveness and safety remains scarce …

Background: Treatment with cladribine tablets (CladT), an immune reconstitution therapy for
relapsing multiple sclerosis (RMS), involves two short courses of treatment in Year 1 and …

Background Cladribine tablets for adult patients with highly active relapsing multiple
sclerosis (MS) have been available in Finland since 2018. Real-world data from different …

The main aim of the study is to evaluate the efficacy and safety profile of ocrelizumab (OCR),
rituximab (RTX), and cladribine (CLA), employed as natalizumab (NTZ) exit strategies in …

The next stage for robotics development is to introduce autonomy and cooperation with
human agents in tasks that require high levels of precision and/or that exert considerable …

Background Today, there are no recommendations on switching disease-modifying
treatments (DMTs) in multiple sclerosis (MS). Objectives To establish guidelines on …

Background Previously, several studies investigated the effect of cladribine among patients
with multiple sclerosis (MS) as a treatment option. Due to the contradictory results of …

Background Cladribine tablets are a highly effective immune reconstitution therapy licensed
for treating relapsing multiple sclerosis (RMS) in Europe since 2017. Currently, there is a …

Background: Cladribine tablets are a highly effective option for the treatment of
relapsingremitting multiple sclerosis (RRMS). Objective: The study aims to evaluate the …